Literature DB >> 21652609

Delayed fingolimod-associated asystole.

Patricio S Espinosa1, Joseph R Berger.   

Abstract

Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21652609     DOI： 10.1177/1352458511410344

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  26 in total

1.  Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.

Authors:  Victor Voon; Lavanya Saiva; Sara O'Kelly; David Keane
Journal:  Eur J Clin Pharmacol       Date:  2013-12-06       Impact factor: 2.953

2.  Postmarketing adverse drug reactions: A duty to report?

Authors:  Eran Klein; Dennis Bourdette
Journal:  Neurol Clin Pract       Date:  2013-08

3.  Deliberate fingolimod overdose presenting with delayed hypotension and bradycardia responsive to atropine.

Authors:  M Stephenson; A Wong; J A Rotella; N Crump; F Kerr; S L Greene
Journal:  J Med Toxicol       Date:  2014-06

4.  Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring.

Authors:  Uchida Tomohiko; Masahiro Mori; Uzawa Akiyuki; Saeko Masuda; Mayumi Mutho; Hiroki Masuda; Satoshi Kuwabara
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

Review 5.  Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.

Authors:  Giorgos Bamias; David J Clark; Jesús Rivera-Nieves
Journal:  Curr Drug Targets       Date:  2013-11       Impact factor: 3.465

6.  Fingolimod and cardiac risk: latest findings and clinical implications.

Authors:  Wendy S Vargas; Jai S Perumal
Journal:  Ther Adv Drug Saf       Date:  2013-06

Review 7.  Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Authors:  Burhan Z Chaudhry; Jeffrey A Cohen; Devon S Conway
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

8.  Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction.

Authors:  M Germana Sanna; Kevin P Vincent; Emanuela Repetto; Nhan Nguyen; Steven J Brown; Lusine Abgaryan; Sean W Riley; Nora B Leaf; Stuart M Cahalan; William B Kiosses; Yasushi Kohno; Joan Heller Brown; Andrew D McCulloch; Hugh Rosen; Pedro J Gonzalez-Cabrera
Journal:  Mol Pharmacol       Date:  2015-10-22       Impact factor: 4.436

9.  Early tolerability and safety of fingolimod in clinical practice.

Authors:  Daniel Ontaneda; Claire Hara-Cleaver; Richard A Rudick; Jeffrey A Cohen; Robert A Bermel
Journal:  J Neurol Sci       Date:  2012-10-03       Impact factor: 3.181

Review 10.  Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.

Authors:  Daniel Ontaneda; Daniela Di Capua
Journal:  Ther Adv Drug Saf       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.